Symbols / AMGN
AMGN Chart
About
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Gen | Market Cap | 206.39B |
| Enterprise Value | 252.70B | Income | 7.71B | Sales | 36.75B |
| Book/sh | 16.07 | Cash/sh | 16.93 | Dividend Yield | 252.00% |
| Payout | 66.90% | Employees | 31500 | IPO | — |
| P/E | 26.89 | Forward P/E | 16.46 | PEG | — |
| P/S | 5.62 | P/B | 23.83 | P/C | — |
| EV/EBITDA | 15.21 | EV/Sales | 6.88 | Quick Ratio | 0.73 |
| Current Ratio | 1.14 | Debt/Eq | 640.27 | LT Debt/Eq | — |
| EPS (ttm) | 14.24 | EPS next Y | 23.26 | EPS Growth | 112.10% |
| Revenue Growth | 8.60% | Earnings | 2026-04-30 | ROA | 7.93% |
| ROE | 106.10% | ROIC | — | Gross Margin | 70.78% |
| Oper. Margin | 30.55% | Profit Margin | 20.98% | Shs Outstand | 539.07M |
| Shs Float | 537.72M | Short Float | 2.47% | Short Ratio | 5.06 |
| Short Interest | — | 52W High | 385.12 | 52W Low | 261.43 |
| Beta | 0.47 | Avg Volume | 2.89M | Volume | 2.36M |
| Target Price | $350.04 | Recom | Buy | Prev Close | $379.42 |
| Price | $382.87 | Change | 0.91% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$350.04
Mean price target
2. Current target
$382.87
Latest analyst target
3. DCF / Fair value
$250.49
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$382.87
Low
$200.00
High
$432.00
Mean
$350.04
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-20 | init | Barclays | — → Equal-Weight | $350 |
| 2026-02-19 | main | Wells Fargo | Equal-Weight → Equal-Weight | $375 |
| 2026-02-18 | main | Piper Sandler | Overweight → Overweight | $432 |
| 2026-02-06 | main | Argus Research | Buy → Buy | $400 |
| 2026-02-06 | main | Guggenheim | Neutral → Neutral | $347 |
| 2026-02-04 | main | Citigroup | Neutral → Neutral | $345 |
| 2026-02-04 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $309 |
| 2026-02-04 | main | Cantor Fitzgerald | Neutral → Neutral | $350 |
| 2026-02-04 | main | Leerink Partners | Outperform → Outperform | $355 |
| 2026-01-26 | main | UBS | Buy → Buy | $390 |
| 2026-01-20 | down | Bernstein | Outperform → Market Perform | $335 |
| 2026-01-08 | main | Truist Securities | Hold → Hold | $319 |
| 2025-12-12 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $304 |
| 2025-12-10 | main | Wells Fargo | Equal-Weight → Equal-Weight | $325 |
| 2025-12-03 | main | BMO Capital | Outperform → Outperform | $372 |
| 2025-11-27 | main | Leerink Partners | Outperform → Outperform | $305 |
| 2025-11-14 | main | Piper Sandler | Overweight → Overweight | $381 |
| 2025-11-06 | main | Cantor Fitzgerald | Neutral → Neutral | $315 |
| 2025-11-05 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $329 |
| 2025-11-05 | main | Wells Fargo | Overweight → Overweight | $300 |
- Evaluating Amgen (AMGN) After Barclays Coverage And Strong Q4 2025 Portfolio Momentum - simplywall.st Wed, 25 Feb 2026 10
- Amgen VP Busch sells $375k in AMGN stock - Investing.com Sat, 21 Feb 2026 01
- Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance Fri, 20 Feb 2026 14
- AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS - PR Newswire ue, 03 Feb 2026 08
- Insider Sale: VP of $AMGN Sells 1,000 Shares - Quiver Quantitative Sat, 21 Feb 2026 00
- Amgen (AMGN) Stock Hits 52-Week Highs: Buy Signal? - Zacks Investment Research Wed, 04 Feb 2026 08
- Amgen Inc. $AMGN Shares Sold by M. Kulyk & Associates LLC - MarketBeat ue, 24 Feb 2026 11
- Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan - BioPharma Dive Wed, 04 Feb 2026 08
- Why Amgen Stock Is Paying Off Big For Long-Term Investors - Forbes Wed, 04 Feb 2026 08
- Stocks making the biggest moves after hours: Chipotle, Advanced Micro Devices, Amgen and more - CNBC ue, 03 Feb 2026 08
- Amgen Stock Is Up 14% This Year on Dual Drug Approvals. Can the Rally Hold? - TIKR.com Wed, 18 Feb 2026 08
- Barclays Initiates Coverage on Amgen (AMGN) with Equal-Weight Ra - GuruFocus Fri, 20 Feb 2026 15
- Is Amgen (AMGN) Still Attractively Priced After Strong Multi Year Share Price Gains - simplywall.st Mon, 23 Feb 2026 04
- Amgen (AMGN) Valuation Check After Recent Share Price Strength And Analyst Fair Value Debate - Yahoo Finance ue, 24 Feb 2026 09
- Barclays initiates Amgen stock coverage with Equalweight rating - Investing.com Fri, 20 Feb 2026 12
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1000 | 375790 | — | Sale at price 375.79 per share. | BUSCH MATTHEW C. | Officer | — | 2026-02-19 00:00:00 | D |
| 1 | 3139 | 1058667 | — | Sale at price 337.26 per share. | GRYGIEL NANCY A | Officer | — | 2025-11-20 00:00:00 | D |
| 2 | 3139 | 532691 | — | Conversion of Exercise of derivative security at price 162.60 - 177.46 per share. | GRYGIEL NANCY A | Officer | — | 2025-11-20 00:00:00 | D |
| 3 | 6879 | 2317071 | — | Sale at price 336.83 per share. | GORDON MURDO | Officer | — | 2025-11-12 00:00:00 | D |
| 4 | 6799 | — | — | Stock Gift at price 0.00 per share. | REESE DAVID M. | Chief Technology Officer | — | 2025-11-12 00:00:00 | D |
| 5 | 890 | 299256 | — | Sale at price 336.24 per share. | KHOSLA RACHNA | Officer | — | 2025-11-12 00:00:00 | D |
| 6 | 218 | — | — | Stock Award(Grant) at price 0.00 per share. | ISHRAK OMAR SYED | Director | — | 2025-11-07 00:00:00 | D |
| 7 | 265 | — | — | Stock Award(Grant) at price 0.00 per share. | HOLLEY CHARLES M JR | Director | — | 2025-11-07 00:00:00 | D |
| 8 | 218 | — | — | Stock Award(Grant) at price 0.00 per share. | DRAKE MICHAEL V | Director | — | 2025-11-07 00:00:00 | D |
| 9 | 1267 | 376280 | — | Sale at price 296.98 per share. | GRYGIEL NANCY A | Officer | — | 2025-08-20 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.14 | 0.11 | 0.14 | 0.11 |
| NormalizedEBITDA | 16.90B | 13.36B | 14.80B | 12.17B |
| TotalUnusualItems | 0.00 | 0.00 | -1.50B | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | 0.00 | -1.50B | |
| NetIncomeFromContinuingOperationNetMinorityInterest | 7.71B | 4.09B | 6.72B | 6.55B |
| ReconciledDepreciation | 5.17B | 5.59B | 4.07B | 3.42B |
| ReconciledCostOfRevenue | 12.04B | 12.86B | 8.45B | 6.41B |
| EBITDA | 16.90B | 13.36B | 14.80B | 12.17B |
| EBIT | 11.73B | 7.76B | 10.73B | 8.75B |
| NetInterestIncome | -2.75B | -3.15B | -2.88B | -1.41B |
| InterestExpense | 2.75B | 3.15B | 2.88B | 1.41B |
| NormalizedIncome | 7.71B | 4.09B | 6.72B | 6.55B |
| NetIncomeFromContinuingAndDiscontinuedOperation | 7.71B | 4.09B | 6.72B | 6.55B |
| TotalExpenses | 27.67B | 26.17B | 20.29B | 16.76B |
| TotalOperatingIncomeAsReported | 9.08B | 7.26B | 7.90B | 9.57B |
| DilutedAverageShares | 542.00M | 541.00M | 538.00M | 541.00M |
| BasicAverageShares | 538.00M | 537.00M | 535.00M | 538.00M |
| DilutedEPS | 14.23 | 7.56 | 12.49 | 12.11 |
| BasicEPS | 14.33 | 7.62 | 12.56 | 12.18 |
| DilutedNIAvailtoComStockholders | 7.71B | 4.09B | 6.72B | 6.55B |
| NetIncomeCommonStockholders | 7.71B | 4.09B | 6.72B | 6.55B |
| NetIncome | 7.71B | 4.09B | 6.72B | 6.55B |
| NetIncomeIncludingNoncontrollingInterests | 7.71B | 4.09B | 6.72B | 6.55B |
| NetIncomeContinuousOperations | 7.71B | 4.09B | 6.72B | 6.55B |
| TaxProvision | 1.26B | 519.00M | 1.14B | 794.00M |
| PretaxIncome | 8.98B | 4.61B | 7.86B | 7.35B |
| OtherIncomeExpense | 2.65B | 506.00M | 2.83B | -814.00M |
| OtherNonOperatingIncomeExpenses | 2.65B | 506.00M | 2.83B | -814.00M |
| SpecialIncomeCharges | 0.00 | 0.00 | -1.50B | |
| OtherSpecialCharges | 1.50B | |||
| NetNonOperatingInterestIncomeExpense | -2.75B | -3.15B | -2.88B | -1.41B |
| InterestExpenseNonOperating | 2.75B | 3.15B | 2.88B | 1.41B |
| OperatingIncome | 9.08B | 7.26B | 7.90B | 9.57B |
| OperatingExpense | 15.63B | 13.31B | 11.84B | 10.35B |
| OtherOperatingExpenses | 1.31B | 248.00M | 879.00M | 503.00M |
| ResearchAndDevelopment | 7.27B | 5.96B | 4.78B | 4.43B |
| SellingGeneralAndAdministration | 7.05B | 7.10B | 6.18B | 5.41B |
| GrossProfit | 24.71B | 20.57B | 19.74B | 19.92B |
| CostOfRevenue | 12.04B | 12.86B | 8.45B | 6.41B |
| TotalRevenue | 36.75B | 33.42B | 28.19B | 26.32B |
| OperatingRevenue | 35.15B | 32.03B | 26.91B | 24.80B |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 538.80M | 537.00M | 535.40M | 534.00M |
| ShareIssued | 538.80M | 537.00M | 535.40M | 534.00M |
| NetDebt | 45.48B | 48.13B | 53.67B | 31.32B |
| TotalDebt | 54.60B | 60.10B | 64.61B | 38.95B |
| TangibleBookValue | -32.30B | -40.46B | -45.04B | -27.95B |
| InvestedCapital | 63.26B | 65.98B | 70.84B | 42.61B |
| WorkingCapital | 3.57B | 5.93B | 11.94B | 6.50B |
| NetTangibleAssets | -32.30B | -40.46B | -45.04B | -27.95B |
| CommonStockEquity | 8.66B | 5.88B | 6.23B | 3.66B |
| TotalCapitalization | 58.66B | 62.43B | 69.40B | 41.02B |
| TotalEquityGrossMinorityInterest | 8.66B | 5.88B | 6.23B | 3.66B |
| StockholdersEquity | 8.66B | 5.88B | 6.23B | 3.66B |
| GainsLossesNotAffectingRetainedEarnings | -258.00M | -66.00M | -289.00M | -231.00M |
| OtherEquityAdjustments | -56.00M | 308.00M | 9.00M | 117.00M |
| ForeignCurrencyTranslationAdjustments | -202.00M | -374.00M | -298.00M | -348.00M |
| UnrealizedGainLoss | 0.00 | 0.00 | 0.00 | |
| RetainedEarnings | -25.11B | -27.59B | -26.55B | -28.62B |
| CapitalStock | 34.02B | 33.53B | 33.07B | 32.51B |
| CommonStock | 34.02B | 33.53B | 33.07B | 32.51B |
| TotalLiabilitiesNetMinorityInterest | 81.93B | 85.96B | 90.92B | 61.46B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 56.44B | 62.86B | 72.53B | 45.77B |
| OtherNonCurrentLiabilities | 2.38B | 2.35B | 2.33B | 2.65B |
| TradeandOtherPayablesNonCurrent | 2.69B | 2.35B | 4.68B | 5.76B |
| NonCurrentDeferredLiabilities | 1.37B | 1.62B | 2.35B | 11.00M |
| NonCurrentDeferredTaxesLiabilities | 1.37B | 1.62B | 2.35B | 11.00M |
| LongTermDebtAndCapitalLeaseObligation | 50.01B | 56.55B | 63.17B | 37.35B |
| LongTermDebt | 50.01B | 56.55B | 63.17B | 37.35B |
| CurrentLiabilities | 25.49B | 23.10B | 18.39B | 15.69B |
| CurrentDebtAndCapitalLeaseObligation | 4.60B | 3.55B | 1.44B | 1.59B |
| CurrentDebt | 4.60B | 3.55B | 1.44B | 1.59B |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.44B | 1.33B | 1.38B | 1.10B |
| CurrentProvisions | 548.00M | 542.00M | ||
| PayablesAndAccruedExpenses | 19.45B | 18.22B | 15.57B | 13.00B |
| CurrentAccruedExpenses | 15.35B | 12.45B | 11.11B | 9.09B |
| InterestPayable | 867.00M | 936.00M | 470.00M | |
| Payables | 4.10B | 5.77B | 4.46B | 3.90B |
| DividendsPayable | 1.36B | 1.28B | 1.21B | 1.14B |
| TotalTaxPayable | 379.00M | 2.58B | 1.66B | 1.20B |
| IncomeTaxPayable | 379.00M | 2.58B | 1.66B | 1.20B |
| AccountsPayable | 2.37B | 1.91B | 1.59B | 1.57B |
| TotalAssets | 90.59B | 91.84B | 97.15B | 65.12B |
| TotalNonCurrentAssets | 61.53B | 62.81B | 66.82B | 42.94B |
| OtherNonCurrentAssets | 12.66B | 9.93B | 9.61B | 5.90B |
| GoodwillAndOtherIntangibleAssets | 40.96B | 46.34B | 51.27B | 31.61B |
| OtherIntangibleAssets | 22.28B | 27.70B | 32.64B | 16.08B |
| Goodwill | 18.68B | 18.64B | 18.63B | 15.53B |
| NetPPE | 7.91B | 6.54B | 5.94B | 5.43B |
| AccumulatedDepreciation | -11.12B | -10.39B | -9.81B | -9.28B |
| GrossPPE | 19.03B | 16.93B | 15.75B | 14.71B |
| ConstructionInProgress | 3.39B | 2.05B | 1.55B | 1.21B |
| OtherProperties | 5.22B | 5.00B | 4.81B | 4.68B |
| MachineryFurnitureEquipment | 5.14B | 4.73B | 4.54B | 4.32B |
| BuildingsAndImprovements | 4.93B | 4.80B | 4.51B | 4.20B |
| LandAndImprovements | 348.00M | 346.00M | 339.00M | 292.00M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 29.06B | 29.03B | 30.33B | 22.19B |
| OtherCurrentAssets | 1.19B | 1.14B | 281.00M | 355.00M |
| PrepaidAssets | 2.94B | 2.14B | 1.65B | 1.20B |
| Inventory | 6.22B | 7.00B | 9.52B | 4.93B |
| FinishedGoods | 1.89B | 2.06B | 2.78B | 1.00B |
| WorkInProcess | 3.42B | 4.12B | 5.75B | 3.10B |
| RawMaterials | 915.00M | 818.00M | 993.00M | 828.00M |
| Receivables | 9.57B | 6.78B | 7.94B | 6.39B |
| DuefromRelatedPartiesCurrent | 521.00M | 502.00M | 700.00M | 780.00M |
| TaxesReceivable | 198.00M | 172.00M | 129.00M | 164.00M |
| AccountsReceivable | 9.57B | 6.78B | 7.27B | 5.56B |
| CashCashEquivalentsAndShortTermInvestments | 9.13B | 11.97B | 10.94B | 9.30B |
| OtherShortTermInvestments | 0.00 | 1.68B | 48.00M | |
| CashAndCashEquivalents | 9.13B | 11.97B | 10.94B | 7.63B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 8.10B | 10.39B | 7.36B | 8.79B |
| RepurchaseOfCapitalStock | 0.00 | -200.00M | 0.00 | -6.36B |
| RepaymentOfDebt | -5.00B | -3.60B | -1.45B | 0.00 |
| IssuanceOfDebt | 0.00 | 0.00 | 27.78B | 6.92B |
| CapitalExpenditure | -1.86B | -1.10B | -1.11B | -936.00M |
| EndCashPosition | 9.13B | 11.97B | 10.94B | 7.63B |
| BeginningCashPosition | 11.97B | 10.94B | 7.63B | 7.99B |
| ChangesInCash | -2.84B | 1.03B | 3.31B | -360.00M |
| FinancingCashFlow | -10.86B | -9.41B | 21.05B | -4.04B |
| CashFlowFromContinuingFinancingActivities | -10.86B | -9.41B | 21.05B | -4.04B |
| NetOtherFinancingCharges | -735.00M | -783.00M | -719.00M | -400.00M |
| CashDividendsPaid | -5.12B | -4.83B | -4.56B | -4.20B |
| CommonStockDividendPaid | -5.12B | -4.83B | -4.56B | -4.20B |
| NetCommonStockIssuance | 0.00 | -200.00M | 0.00 | -6.36B |
| CommonStockPayments | 0.00 | -200.00M | 0.00 | -6.36B |
| NetIssuancePaymentsOfDebt | -5.00B | -3.60B | 26.32B | 6.92B |
| NetLongTermDebtIssuance | -5.00B | -3.60B | 26.32B | 6.92B |
| LongTermDebtPayments | -5.00B | -3.60B | -1.45B | 0.00 |
| LongTermDebtIssuance | 0.00 | 0.00 | 27.78B | 6.92B |
| InvestingCashFlow | -1.94B | -1.05B | -26.20B | -6.04B |
| CashFlowFromContinuingInvestingActivities | -1.94B | -1.05B | -26.20B | -6.04B |
| NetOtherInvestingChanges | -32.00M | 50.00M | 224.00M | 100.00M |
| NetInvestmentPurchaseAndSale | 0.00 | 0.00 | 1.67B | -1.37B |
| SaleOfInvestment | 0.00 | 0.00 | 1.67B | 1.22B |
| PurchaseOfInvestment | 0.00 | -1.00M | -2.59B | -8.90B |
| NetBusinessPurchaseAndSale | -53.00M | 0.00 | -26.99B | -3.84B |
| SaleOfBusiness | 130.00M | 0.00 | ||
| PurchaseOfBusiness | -53.00M | 0.00 | -26.99B | -3.84B |
| NetPPEPurchaseAndSale | -1.86B | -1.10B | -1.11B | -936.00M |
| PurchaseOfPPE | -1.86B | -1.10B | -1.11B | -936.00M |
| OperatingCashFlow | 9.96B | 11.49B | 8.47B | 9.72B |
| CashFlowFromContinuingOperatingActivities | 9.96B | 11.49B | 8.47B | 9.72B |
| ChangeInWorkingCapital | -1.98B | 2.37B | -484.00M | -733.00M |
| ChangeInOtherWorkingCapital | 499.00M | 92.00M | 953.00M | |
| ChangeInOtherCurrentLiabilities | -156.00M | -51.00M | -222.00M | -182.00M |
| ChangeInOtherCurrentAssets | -1.27B | -652.00M | -564.00M | 258.00M |
| ChangeInPayablesAndAccruedExpense | 736.00M | 3.00M | -127.00M | 679.00M |
| ChangeInAccruedExpense | 2.06B | 1.19B | 935.00M | 943.00M |
| ChangeInPayable | -1.33B | -1.19B | -1.06B | -264.00M |
| ChangeInAccountPayable | 428.00M | 312.00M | -402.00M | 154.00M |
| ChangeInTaxPayable | -1.76B | -1.50B | -660.00M | -418.00M |
| ChangeInIncomeTaxPayable | -1.76B | -1.50B | -660.00M | -418.00M |
| ChangeInInventory | 886.00M | 2.53B | 491.00M | -742.00M |
| ChangeInReceivables | -2.68B | 441.00M | -1.01B | -746.00M |
| ChangesInAccountReceivables | -2.68B | 441.00M | -1.01B | -746.00M |
| OtherNonCashItems | 149.00M | -177.00M | -277.00M | -303.00M |
| StockBasedCompensation | 494.00M | 530.00M | 431.00M | 401.00M |
| AssetImpairmentCharge | 1.20B | 159.00M | 851.00M | |
| DeferredTax | -721.00M | -1.23B | -1.27B | -1.20B |
| DeferredIncomeTax | -721.00M | -1.23B | -1.27B | -1.20B |
| DepreciationAmortizationDepletion | 5.17B | 5.59B | 4.07B | 3.42B |
| DepreciationAndAmortization | 5.17B | 5.59B | 4.07B | 3.42B |
| Depreciation | 5.17B | 5.59B | 4.07B | 3.42B |
| OperatingGainsLosses | -2.06B | 159.00M | -1.56B | 1.58B |
| EarningsLossesFromEquityInvestments | -10.00M | 11.00M | 891.00M | 33.00M |
| GainLossOnInvestmentSecurities | -2.06B | 159.00M | -1.56B | 127.00M |
| GainLossOnSaleOfBusiness | 0.00 | 0.00 | 567.00M | 0.00 |
| NetIncomeFromContinuingOperations | 7.71B | 4.09B | 6.72B | 6.55B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AMGN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|